Zoetis Inc. (ZTS) – Can Zoetis gain back its momentum?

Zoetis Inc. (ZTS) (Q1FY23)

Introduction

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners.

Highlights

Zoetis witnessed significant growth in their livestock portfolio, with a 12% operational increase. This growth was diverse and encompassed various sectors, including cattle, poultry, sheep, and fish. On the other hand, the company’s companion animal revenue remained stable operationally.

Stock performance

Zoetis’s stock price showed a volatile trend in past 3-months period. It increased by 1.1% during the period. The stock price declined by 3.49% in past 1-year. The stock has a 52- week high of $187.82 and its 52-week low is $124.15.

In the past 3 years, the stock has given returns of 26.29%. ZTS has a 50-day moving Avg. and 200-day moving Avg. of $173.54 and $160.78, respectively.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates